1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
68ganota-anti-mmr-vhh2 Non-Small Cell Lung Carcinoma	Universitair Ziekenhuis Brussel	P2	D (30)
atl001 Non-Small Cell Lung Carcinoma	Achilles Therapeutics UK Limited	P2	D (30)
Lifei Xiaoji Wan Non-Small Cell Lung Carcinoma	Henan University of Traditional Chinese Medicine	N/A	D (30)
Marcaine Non-Small Cell Lung Carcinoma	Hacettepe University	N/A	D (30)
Milademetan Non-Small Cell Lung Carcinoma	Rain Oncology Inc	P1/2	D (30)
Tusamitamab Ravtansine Non-Small Cell Lung Carcinoma	Innovent Biologics (Suzhou) Co. Ltd.	P3	D (30)
Luveltamab Tazevibulin Non-Small Cell Lung Carcinoma	Sutro Biopharma, Inc.	P2	D (29)
Nanrilkefusp Alfa Non-Small Cell Lung Carcinoma	SOTIO Biotech AG	P2	D (28)
Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) Non-Small Cell Lung Carcinoma	Sanofi	P2	D (27)
Leucogen Non-Small Cell Lung Carcinoma	Fudan University	N/A	D (26)
Mass-Dispersesing Decoction Non-Small Cell Lung Carcinoma	Guangzhou University of Traditional Chinese Medicine	N/A	D (26)
Tarloxotinib Non-Small Cell Lung Carcinoma	Medical University of South Carolina	P2	D (26)
Teplizumab-Mzwv Non-Small Cell Lung Carcinoma	Grit Biotechnology	N/A	D (26)
afm24 Non-Small Cell Lung Carcinoma	NKGen Biotech, Inc.	P1/2	D (24)
Bms-986466 Non-Small Cell Lung Carcinoma	LianBio LLC	P1	D (23)
gt201 Non-Small Cell Lung Carcinoma	Grit Biotechnology	N/A	D (22)
Adebellizumab Non-Small Cell Lung Carcinoma	The First Affiliated Hospital of Guangzhou Medical University	P2	NR ()
Adibelimab Non-Small Cell Lung Carcinoma	Second Affiliated Hospital of Xi'an Jiaotong University	P2	NR ()
aer101 Non-Small Cell Lung Carcinoma	University of Oklahoma	Early P1	NR ()
ak105,anrotinib Non-Small Cell Lung Carcinoma	Qiming Wang	P4	NR ()
ak129 Non-Small Cell Lung Carcinoma	Akeso	P1/2	NR ()
al2846 Non-Small Cell Lung Carcinoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P3	NR ()
an0025 Non-Small Cell Lung Carcinoma	Adlai Nortye Biopharma Co., Ltd.	P1	NR ()
Anti-Trop2 Car-Nk Cell Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P1/2	NR ()
Apalolimab Non-Small Cell Lung Carcinoma	Jiangsu Cancer Institute & Hospital	P2	NR ()
Aqua07 Non-Small Cell Lung Carcinoma	Chugai Pharmaceutical	P1	NR ()
asp3082 Non-Small Cell Lung Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P2	NR ()
azd9592 Non-Small Cell Lung Carcinoma	AstraZeneca	P1	NR ()
Cetuximab Beta Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	NR ()
CFT8919 Non-Small Cell Lung Carcinoma	Betta Pharmaceuticals Co., Ltd.	P1	NR ()
Clopidogrel Non-Small Cell Lung Carcinoma	Shanghai Chest Hospital	P3	NR ()
Decoy20 Non-Small Cell Lung Carcinoma	Indaptus Therapeutics, Inc	P1/2	NR ()
Efgbemalenograstim Alfa Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	NR ()
Epi-326 Non-Small Cell Lung Carcinoma	EpiBiologics	P1	NR ()
Evoximab Non-Small Cell Lung Carcinoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	NR ()
gfh018 Non-Small Cell Lung Carcinoma	Genfleet Therapeutics (Shanghai) Inc.	P2	NR ()
hlx42 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P1	NR ()
hy1272 Non-Small Cell Lung Carcinoma	Newsoara Biopharma Co., Ltd.	P1	NR ()
Ilkn421H Non-Small Cell Lung Carcinoma	iLeukon Therapeutics, Inc.	P2	NR ()
Inv-8989 Non-Small Cell Lung Carcinoma	Shenzhen Ionova Life Sciences Co., Ltd.	P1/2	NR ()
Iruplinalib Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	NR ()
Kst-6051 Non-Small Cell Lung Carcinoma	Kestrel Therapeutics, Inc.	P1	NR ()
Ladarixin Non-Small Cell Lung Carcinoma	NYU Langone Health	P2	NR ()
Limertinib Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P3	NR ()
Magnesium Diasporal Non-Small Cell Lung Carcinoma	Swiss Cancer Institute	P2/3	NR ()
Mdna11 Non-Small Cell Lung Carcinoma	Medicenna Therapeutics, Inc.	P1/2	NR ()
Methoxyamine Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P2	NR ()

Showing 1051 to 1100 of 1,125 assets

PreviousPage 22 of 23Next